SCHEMBL5505248

SCHEMBL5505248

C=COCC.CCOC(OCC)[C@H]1CCCC(=O)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6386752 0.89 BACE1 (0.31)
SCHEMBL5747380 0.89 BACE1 (0.31)
SCHEMBL9870670 0.79 MEN1 (0.32)
SCHEMBL9865636 0.79 MEN1 (0.32)
SCHEMBL6604249 0.79 MEN1 (0.32)
SCHEMBL4511068 0.77 IRAK4 (0.33)
SCHEMBL4511069 0.77 IRAK4 (0.33)
SCHEMBL9666729 0.69
Caprolactam SCHEMBL28275090 0.66 CRBN (0.53)
SCHEMBL2603209 0.65 CRBN (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841733-A2 SUBSTITUTED PYRROLIDONE COMPOUNDS AS PROSTAGLANDIN EP4 AGONISTS Allergan, Inc. (US) 2007-10-10 EP disclosed
EP-1722795-A1 PIPERIDINYL PROSTAGLANDIN E ANALOGS Allergan, Inc. (US) 2006-11-22 EP disclosed
WO-2006052893-A2 SUBSTITUTED PYRROLIDONE COMPOUNDS AS EP4 AGONISTS ALLERGAN, INC. (US) 2006-05-18 WO disclosed
WO-2005072735-A1 PIPERIDINYL PROSTAGLANDIN E ANALOGS ALLERGAN, INC. (US) 2005-08-11 WO disclosed